TY - JOUR
T1 - Polymer-based nanoparticles for cancer theranostics: advances, challenges, and future perspectives
AU - Shanahan, Kaylin
AU - Coen, Daniel
AU - Nafo, Wanis
PY - 2025/7/30
Y1 - 2025/7/30
N2 - Polymer-based nanoparticles have emerged as powerful multifunctional platforms in cancer theranostics, offering the ability to integrate diagnostic imaging and targeted therapy within a single system. These nanocarriers enable improved tumor localization, enhanced contrast agent delivery, and controlled therapeutic release, addressing limitations associated with conventional contrast agents such as poor specificity, rapid clearance, and systemic toxicity. Advances in polymer chemistry and nanoparticle fabrication methods, including solvent evaporation, nanoprecipitation, emulsion-diffusion, and emulsion polymerization, have allowed precise control over particle size, surface charge, and drug-loading efficiency, optimizing biodistribution and imaging performance. Hybrid polymer-inorganic nanoparticles further expand functionality by incorporating magnetic, optical, or radiopaque components, enabling multimodal imaging and stimuli-responsive drug release while maintaining biocompatibility. Key factors influencing the efficiency of polymer nanoparticle-based contrast agents include physicochemical properties such as particle size, morphology, surface functionalization, and responsiveness to tumor microenvironmental stimuli. These attributes collectively govern circulation time, cellular uptake, and accumulation in tumor tissues via passive and active targeting strategies. While promising, the clinical translation of these systems faces challenges including immunogenicity, pharmacokinetic variability, long-term safety concerns, and manufacturing scalability. Recent innovations in ligand functionalization, biomimetic coatings, and multifunctional nanoparticle design continue to advance therapeutic specificity and imaging precision, positioning polymer nanoparticles as versatile candidates for personalized oncologic care. This review provides a comprehensive synthesis of current methods for contrast agent integration, the role of physicochemical properties in performance, biological interactions, safety considerations, recent design innovations, translational barriers, and future research directions for polymer nanoparticle-based cancer theranostics.
AB - Polymer-based nanoparticles have emerged as powerful multifunctional platforms in cancer theranostics, offering the ability to integrate diagnostic imaging and targeted therapy within a single system. These nanocarriers enable improved tumor localization, enhanced contrast agent delivery, and controlled therapeutic release, addressing limitations associated with conventional contrast agents such as poor specificity, rapid clearance, and systemic toxicity. Advances in polymer chemistry and nanoparticle fabrication methods, including solvent evaporation, nanoprecipitation, emulsion-diffusion, and emulsion polymerization, have allowed precise control over particle size, surface charge, and drug-loading efficiency, optimizing biodistribution and imaging performance. Hybrid polymer-inorganic nanoparticles further expand functionality by incorporating magnetic, optical, or radiopaque components, enabling multimodal imaging and stimuli-responsive drug release while maintaining biocompatibility. Key factors influencing the efficiency of polymer nanoparticle-based contrast agents include physicochemical properties such as particle size, morphology, surface functionalization, and responsiveness to tumor microenvironmental stimuli. These attributes collectively govern circulation time, cellular uptake, and accumulation in tumor tissues via passive and active targeting strategies. While promising, the clinical translation of these systems faces challenges including immunogenicity, pharmacokinetic variability, long-term safety concerns, and manufacturing scalability. Recent innovations in ligand functionalization, biomimetic coatings, and multifunctional nanoparticle design continue to advance therapeutic specificity and imaging precision, positioning polymer nanoparticles as versatile candidates for personalized oncologic care. This review provides a comprehensive synthesis of current methods for contrast agent integration, the role of physicochemical properties in performance, biological interactions, safety considerations, recent design innovations, translational barriers, and future research directions for polymer nanoparticle-based cancer theranostics.
U2 - 10.37349/ebmx.2025.101342
DO - 10.37349/ebmx.2025.101342
M3 - Review article
SN - 2996-9476
JO - Exploration of BioMat-X
JF - Exploration of BioMat-X
ER -